The impact of weekly semaglutide, a glucagon-like peptide-1 agonist, on kidney outcomes in adults with type 2 diabetes mellitus

The impact of weekly semaglutide, a glucagon-like peptide-1 agonist, on kidney outcomes in adults with type 2 diabetes mellitus

Background: Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder associated with kidney complications. This study aims to investigate the effects of weekly subcutaneous semaglutide, a GLP-1 agonist, on kidney outcomes. Methods: This retrospective cohort study was conducted in nephrology a...

Full description

Bibliographic Details
Main Authors:	Ahmad A Algarni, Fahad S Alqarni, Hanin A Shalaby
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2024-01-01
Series:	Journal of Family Medicine and Primary Care
Subjects:	albuminuria chronic kidney disease egfr glucagon-like peptide-1 receptor agonists semaglutide type 2 diabetes
Online Access:	http://www.jfmpc.com/article.asp?issn=2249-4863;year=2024;volume=13;issue=2;spage=532;epage=536;aulast=Algarni

Similar Items

Clinical Impact of Semaglutide, a Glucagon-Like Peptide-1 Receptor Agonist, on Obesity Management: A Review
by: Alorfi NM, et al.
Published: (2022-08-01)

An Effective Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Improves Sarcopenic Obesity in Obese Mice by Modulating Skeletal Muscle Metabolism
by: Ren Q, et al.
Published: (2022-10-01)

Glucagon‐like peptide‐1 receptor agonists and kidney outcomes
by: Richard J. MacIsaac, et al.
Published: (2024-10-01)

Semaglutide in Cardiometabolic Diseases: SELECTing the Target Population
by: Francesco Natale, et al.
Published: (2024-05-01)

Efficacy and tolerability of oral semaglutide in Japanese patients with type 2 diabetes mellitus: Analysis report from diabetes specialist clinics
by: Tetsuaki Inokuchi, et al.
Published: (2024-09-01)

Glucagon-like Peptide-1 Receptor Agonists: Are They as Good as They Seem? A Systematic Review of Severe Adverse Effects
by: Pranjal Sharma, et al.
Published: (2024-08-01)

Efficacy and Safety of Semaglutide, a Glucagon-Like Peptide-1 Receptor Agonist in Real-Life: A Case Series of Patients in Maintenance Incremental Hemodialysis
by: José C. De la Flor, et al.
Published: (2022-11-01)

Editorial: Reviews and Novel Clinical Perspectives on Semaglutide: A GLP-1 Receptor Agonist With Both Injectable and Oral Formulations
by: Juris J. Meier, et al.
Published: (2021-09-01)

The Impact of Glucagon-like Peptide 1 Receptor Agonists on Obstructive Sleep Apnoea: A Scoping Review
by: Khang Duy Ricky Le, et al.
Published: (2024-01-01)

Semaglutide and kidney function: friends or enemies?
by: Federica Giofrè, et al.
Published: (2024-02-01)

Anti-obesity therapy for cardiovascular disease prevention: potential expected roles of glucagon-like peptide-1 receptor agonists
by: Kosuke Sawami, et al.
Published: (2022-09-01)

Effect of glucagon-like peptide-1 receptor agonists on vascular risk factors among adults with type 2 diabetes and established atherosclerotic cardiovascular disease
by: Aaron King, et al.
Published: (2025-03-01)

Effects of semaglutide on gut microbiota, cognitive function and inflammation in obese mice
by: Jing Feng, et al.
Published: (2024-08-01)

Emerging role of GLP-1 agonists in cardio-metabolic therapy - Focus on Semaglutide
by: Celestine Odigwe, et al.
Published: (2025-04-01)

Impact of semaglutide on weight and functional outcomes among obese heart failure patients: a propensity scores matching analysis
by: Mahmoud Balata, et al.
Published: (2024-10-01)

Efficacy and Safety of Liraglutide and Semaglutide on Weight Loss in People with Obesity or Overweight: A Systematic Review
by: Xie Z, et al.
Published: (2022-12-01)

Metabolomics Provides Insights into Renoprotective Effects of Semaglutide in Obese Mice
by: Chen X, et al.
Published: (2022-11-01)

Cardiometabolic Modulation by Semaglutide Contributes to Cardioprotection in Rats with Myocardial Infarction
by: Yan H, et al.
Published: (2024-11-01)

Semaglutide-Associated Acute Interstitial Nephritis: A Case Report
by: Megan Borkum, et al.
Published: (2022-12-01)

Insulin–glucagon‐like peptide‐1 receptor agonist relay and glucagon‐like peptide‐1 receptor agonist first regimens in individuals with type 2 diabetes: A randomized, open‐label trial study
by: Yumie Takeshita, et al.
Published: (2022-06-01)

Association of glucagon‐like peptide‐1 receptor‐targeted imaging probe with in vivo glucagon‐like peptide‐1 receptor agonist glucose‐lowering effects
by: Takaaki Murakami, et al.
Published: (2020-11-01)

Anti-inflammatory effect of semaglutide: updated systematic review and meta-analysis
by: Walter Masson, et al.
Published: (2024-07-01)

Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6
by: Michael A. Nauck, et al.
Published: (2021-03-01)

Glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide agonists for the treatment of obesity and diabetes mellitus
by: Alexander C. Martins, et al.
Published: (2024-04-01)

Safety of Semaglutide
by: Mark M. Smits, et al.
Published: (2021-07-01)

Glycemic treatment effect of oral semaglutide plus other antidiabetic medications: An Indian experience
by: Manoj Chawla, et al.
Published: (2022-01-01)

Semaglutide-associated bullous pemphigoid
by: Clayton P. Burruss, BS, et al.
Published: (2021-09-01)

Corrigendum: Safety of Semaglutide
by: Mark M. Smits, et al.
Published: (2021-11-01)

Effect of Switching to Once-Weekly Semaglutide on Non-Alcoholic Fatty Liver Disease: The SWITCH-SEMA 1 Subanalysis
by: Hiroshi Nomoto, et al.
Published: (2023-08-01)

Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
by: Seungah Lee, et al.
Published: (2017-03-01)

Impact of Fasting on Physical Activity Motivation and Weight Reduction in Patients Administered Glucagon-Like Peptide-1 Agonists: A Qualitative Study
by: Almaqhawi A, et al.
Published: (2025-01-01)

Peptidyl and Non-Peptidyl Oral Glucagon-Like Peptide-1 Receptor Agonists
by: Hun Jee Choe, et al.
Published: (2021-02-01)

Effectiveness and safety of semaglutide in overweight/obese adults with or without type 2 diabetes: A systematic review and meta-analysis
by: Liu Yang, et al.
Published: (2024-09-01)

Effectiveness of Oral versus Injectable Semaglutide in Adults with Type 2 Diabetes: Results from a Retrospective Observational Study in Croatia
by: Sanja Klobučar, et al.
Published: (2024-02-01)

Comparative Cardio-Renal Outcomes of Type 2 Diabetes Patients Administered Glucagon-Like Peptide-1 Receptor Agonists: A Network Meta-Analysis
by: Chuanjun Zhuo, et al.
Published: (2021-12-01)

The Impact of Glucagon-Like Peptide 1 Receptor Agonists on Bone Metabolism and Its Possible Mechanisms in Osteoporosis Treatment
by: Baocheng Xie, et al.
Published: (2021-06-01)

The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update
by: Agnieszka Jakubowska, et al.
Published: (2024-02-01)

Nephroprotective potential of glucagon-like peptide-1 receptor agonists
by: Minara S. Shamkhalova, et al.
Published: (2020-04-01)

Oral Semaglutide In The Management Of Type 2 Diabetes: A Report On The Evidence To Date
by: Pearson S, et al.
Published: (2019-12-01)

Glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes: Past, present, and future
by: Sanjay Kalra, et al.
Published: (2016-01-01)